STERIS (STE)
(Delayed Data from NYSE)
$236.01 USD
+1.87 (0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $236.04 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.01 USD
+1.87 (0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $236.04 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q2.
Steris (STE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1.85% and 3.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Steris (STE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Strategic Growth Strong Amid Several Headwinds
by Zacks Equity Research
STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.
Why Is Steris (STE) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q1.
Steris (STE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 2.04% and 0.01%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Intuitive Surgical's FDA Approval for SureForm to Aid Surgery
by Zacks Equity Research
Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.
MASI or STE: Which Is a Better Investment Option Right Now?
by Zacks Equity Research
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.
Here's Why You Must Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS' (STE) acquisition of U.K.-based outsourced sterilization services provider, Synergy Health plc, remains one of its key strategic moves.
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks
by Zacks Equity Research
The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.
Mechatronics for Healthcare: 3 MedTech Stocks to Bet On
by Nabaparna Bhattacharya
Here we analyze how Medical Mechatronics is creating new opportunities in MedTech for investors who are keen on putting their money in the healthcare space for longer-term gains.
Medical Device Industry Outlook - June 2018
by Zacks Equity Research
The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.
Why Is STERIS (STE) Up 5.2% Since Its Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is STERIS (STE) Up 7.7% Since Its Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy STERIS (STE) Ahead of Earnings?
by Zacks Equity Research
STERIS (STE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
4 Top Growth Picks as MedTech Battle Rages On
by Zacks Equity Research
Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
Why Is STERIS (STE) Up 3.5% Since the Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS Continues to Trade Below Industry on Dull Outlook
by Zacks Equity Research
On Mar 16, we issued an updated research report on Ohio-based STERIS plc (STE).
STERIS (STE) Up 3.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.